Table 3.

Kidney transplant recipient characteristics, stratified by DGF

Recipient CharacteristicsAll (n=2435)DGF (n=756)Non-DGF (n=1679)
Age, y53 (15)55 (13)52 (16)
Male gender1493 (61%)496 (66%)997 (59%)
Black race959 (39%)371 (49%)588 (35%)
Hispanic ethnicity279 (11%)79 (10%)200 (12%)
Donor AKI
 No AKI1849 (76%)517 (68%)1332 (79%)
 Stage 1392 (16%)136 (18%)256 (15%)
 Stage 2109 (4%)53 (7%)56 (3%)
 Stage 385 (3%)50 (7%)35 (2%)
Cause of ESRD
 Diabetes 718 (29%)231 (31%)487 (29%)
 Hypertension657 (27%)227 (30%)430 (26%)
 Other or unknown504 (21%)136 (18%)368 (22%)
 GN394 (16%)109 (14%)285 (17%)
 Graft failure162 (7%)53 (7%)109 (6%)
HLA mismatch level
 0153 (6%)27 (4%)126 (8%)
 121 (1%)11 (1%)10 (1%)
 283 (3%)20 (3%)63 (4%)
 3292 (12%)91 (12%)201 (12%)
 4644 (27%)192 (25%)452 (27%)
 5822 (34%)270 (36%)552 (33%)
 6414 (17%)144 (19%)270 (16%)
Panel reactive antibody
 0%1549 (64%)501 (66%)1048 (62%)
 1%–20%178 (7%)59 (8%)119 (7%)
 21%–80%326 (13%)89 (12%)237 (14%)
 >80%382 (16%)107 (14%)275 (16%)
Cold ischemia time, h15.28 (7.09)17.21 (7.14)14.42 (6.90)
Preemptive transplant274 (11%)28 (4%)246 (15%)
Serum creatinine at transplant, µmol/L686 (296)746 (285)659 (297)
  • Values reported are mean (SD) or n (%). Stage 1 AKI was defined as an increase in serum creatinine of ≥26.5 µmol/L or an increase of 1.5-fold from admission to terminal value. Stage 2 was defined as an increase of between two- and three-fold from baseline. Stage 3 was defined as an increase of three-fold from baseline or a serum creatinine of ≥354 µmol/L. HLA, human leukocyte antigen.